There is one clinical trial.
This study is a combined Phase 1 and Phase 2 study with IV infusion of NGM621 to evaluate the safety, tolerability, and PK in healthy volunteers (Part 1), and safety, tolerability, PK and efficacy in subjects with confirmed SARS-CoV-2 infection (Part 2).
Description: TEAEs in subjects receiving NGM621 compared to placeboMeasure: Treatment emergent adverse events - Part 1 Time: 85 days
Description: TEAEs in subjects receiving NGM621 compared to placeboMeasure: Treatment emergent adverse events - Part 2 Time: 91 days
Description: Clnical status (on an 8-point ordinal scale) in NGM621 group versus placebo groupMeasure: Clinical status at Day 15 and Day 29 - Part 2 Time: 29 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports